
In the phase 4 STAR trial, guselkumab improved BASDAI and MRI sacroiliac joint inflammation vs placebo at week 24 in axial psoriatic arthritis.
And now for something a little different . . . 8 medical sentences that could benefit from some editing.
[Editor’s note: This slide show originally appeared on our partner site, Patient Care Online.]






